Media coverage
56
Media coverage
Title Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 13/02/23 URL ct.moreover.com/?a=50001478235&p=1gw&v=1&x=6wNW1HH2gzhPPre-Bm6X_A Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Morningstar.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001107735&p=1gw&v=1&x=mfcAKhMthCW-sWVIcJiKMg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Street Insider Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001094734&p=1gw&v=1&x=J_uEO7fe6W7xR1rUoxvlMA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet BioSpace Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001479480&p=1gw&v=1&x=UAkS1rGp0dPHymTEG4bLng Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet InvestorsObserver Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001104781&p=1gw&v=1&x=MORWVid0-ldZFc2aXBpqOA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Finanzen.net Country/Territory Germany Date 13/02/23 URL ct.moreover.com/?a=50001104888&p=1gw&v=1&x=Ho3vqzI6lnHy3k45T0k4bQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-yearsâ follow-up in first-line advanced renal cell carcinoma Media name/outlet Finanzen.ch Country/Territory Switzerland Date 13/02/23 URL ct.moreover.com/?a=50001120910&p=1gw&v=1&x=sjXcszcsqMUnFhMYtsUpFg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Finanzen.ch Country/Territory Switzerland Date 13/02/23 URL ct.moreover.com/?a=50001141204&p=1gw&v=1&x=cWeNcmBQmS5loanAuh-pkQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Yahoo! Finance Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001155243&p=1gw&v=1&x=c1LgGXS1_pvcbzv4eP0ghg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Yahoo! Finance UK and Ireland Country/Territory United Kingdom Date 13/02/23 URL ct.moreover.com/?a=50001170812&p=1gw&v=1&x=U7SAlQQgF-7wyjHMAdZEVQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet Le Lezard.com Country/Territory Canada Date 13/02/23 URL ct.moreover.com/?a=50001088842&p=1gw&v=1&x=gxyt6ptx0PMnH58khLOnsA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet MarketScreener.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001099261&p=1gw&v=1&x=6MAdXTrIrxFRJ2cSfOZHAA Persons Mauricio Burotto Title Cabometyx(R) in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet TD Ameritrade Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001094478&p=1gw&v=1&x=7zHjOgM-Kvhacf4e7HadwQ Persons Mauricio Burotto Title Cabometyx in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Wallstreet Online Country/Territory Germany Date 13/02/23 URL ct.moreover.com/?a=50001145504&p=1gw&v=1&x=YhuTPENn_qU-FNWaAM44YQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Valuespectrum.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001244540&p=1gw&v=1&x=4NKwwhhSiThoMvx24h5Ecw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet GlobeNewswire Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001107717&p=1gw&v=1&x=4qk0CDfFSUTh4yIpJvc4TQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Yahoo! Sports Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001118849&p=1gw&v=1&x=N8w-mVcnwXgLSR_Qvvo1_Q Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001259712&p=1gw&v=1&x=p_6sP7MceTJ_0HKmB1YgYw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Investegate Country/Territory United Kingdom Date 13/02/23 URL ct.moreover.com/?a=50001097990&p=1gw&v=1&x=4PvL8O8lkSCIW_SEAJGD6g Persons Mauricio Burotto Title Ipsen SA: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire) Media name/outlet Avanza Bank AB Country/Territory Sweden Date 13/02/23 URL ct.moreover.com/?a=50001101856&p=1gw&v=1&x=VkBBihh6AYxHzwvkEafRQg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Ipsen Country/Territory France Date 13/02/23 URL ct.moreover.com/?a=50001188774&p=1gw&v=1&x=WtpjbU2Cvd_3-9ZVTfvQeA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Port Arthur News Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001131587&p=1gw&v=1&x=MUEEdvFNLCi3P6uhqo0Q5w Persons Mauricio Burotto Title Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 13/02/23 URL ct.moreover.com/?a=50001173110&p=1gw&v=1&x=LkUZ3NpG4zJGWozVqKh33g Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Winchester Sun Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001145863&p=1gw&v=1&x=ypuv-6XItoULcHJjenBtNw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Smithfield Times Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001152309&p=1gw&v=1&x=AaRmt0breGybB2ASC8HS6A Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Jessamine Journal Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001153417&p=1gw&v=1&x=SOp8mZxLjmEehZwTvmvbRg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Suffolk News Herald Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001156276&p=1gw&v=1&x=ieodvdhlz07Lr0rKt2NLXg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WIVB Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001161296&p=1gw&v=1&x=cP_YAA9aeA6hk-NRVeIh-g Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Elizabethton.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001169817&p=1gw&v=1&x=EnINAe7YPKUreL_xdmdQWg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet LaGrange Daily News Country/Territory Georgia Date 13/02/23 URL ct.moreover.com/?a=50001170723&p=1gw&v=1&x=2rmnm2sdCQGX2jeMMR0Ufg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WTWO Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001171504&p=1gw&v=1&x=ADKYd7D5O-VuNQS74R4tzA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001172200&p=1gw&v=1&x=gReVEtsRMeOdl-Hf2hBMbQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet KOIN Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001174875&p=1gw&v=1&x=XQtrK6YVNYdDGBK-Wu6NLA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet NBC4 Columbus Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001198270&p=1gw&v=1&x=6ulvScxiENnn0ymyd380rA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet FOX5 San Diego Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001238761&p=1gw&v=1&x=UjH_MzTwaUh8gbtBdHD1zg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WKBN 27 First News Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001250398&p=1gw&v=1&x=4niJ58ApAZGf21JfRjhjAQ Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet BRProud.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001259780&p=1gw&v=1&x=e5rEGkNPiLQ2_kZvdCJMUA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet BizWire Express Country/Territory India Date 13/02/23 URL ct.moreover.com/?a=50001265664&p=1gw&v=1&x=hWfELWXMmuzYs6QOYHrIVA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet PIX11 Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001280387&p=1gw&v=1&x=-sBW5Actiq8TTyxB7h86QA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WGNO Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001302570&p=1gw&v=1&x=pqb0yRW5s8XCb3PxIvp1-g Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet YOUR BASIN Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001304035&p=1gw&v=1&x=qpYWV-8U1Uxw-Nni8Dwa0g Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WJHL.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001310281&p=1gw&v=1&x=eQpHRNfh3bXW_Rg58yo31Q Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet KTLA Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001316027&p=1gw&v=1&x=Vx5svUUmbvU3IMwCLkMZHg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WGN-TV Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001319362&p=1gw&v=1&x=rIWrSa14TBhMIzReWHwoiw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Wood TV Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001325299&p=1gw&v=1&x=H_EpkB_JJsVvxPwt4248Iw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Siouxland Matters Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001332225&p=1gw&v=1&x=EXF2wNEGKxDUt43LYDo3rw Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WTen.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001341003&p=1gw&v=1&x=_ArHKOtbXTs3D4-zbh3TDA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Fox 16 Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001343999&p=1gw&v=1&x=y8u3ufu1HHaBwgp_vk-jrA Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet FOX8 WGHP Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001375138&p=1gw&v=1&x=CPc6kMppyaSHuS1-xADywg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WREG Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001375366&p=1gw&v=1&x=u7vBUx97XDE62V61fSMPjg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet Everything Lubbock Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001380084&p=1gw&v=1&x=HmbuGssESmrLY60VK9Lsew Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet WANE-TV Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001389348&p=1gw&v=1&x=BdiF9WVSWvaWo2FH77aa9w Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet MyPanhandle.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001401213&p=1gw&v=1&x=d-5oi2kGrw7zHNS5zhQ3Bg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma Media name/outlet KFOR.com Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001414213&p=1gw&v=1&x=F6J7QUwMdPZl5LG9PM0GDg Persons Mauricio Burotto Title Cabometyx® in combination with nivolumab shows durable Media name/outlet Life Care News Country/Territory India Date 13/02/23 URL ct.moreover.com/?a=50001679155&p=1gw&v=1&x=BiB6yihxmG7zNiSJUctRTA Persons Mauricio Burotto Title Cabometyx in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line Media name/outlet User Walls Country/Territory United States Date 13/02/23 URL ct.moreover.com/?a=50001099632&p=1gw&v=1&x=pBBjBpX3gMAxYuZuYXnVIA Persons Mauricio Burotto